

Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis

Supplementary Material




Figure S1. Prognostic role of IB-determined ER β status for DFS. DFS, disease-free survival; IB, immunoblot; ER, estrogen receptor.




Figure S2. Prognostic role of PCR-determined ER β status for DFS. DFS, disease-free survival; PCR, polymerase chain reaction; ER, estrogen receptor.




Figure S3. Prognostic role of TMA-determined ER β status for DFS. DFS, disease-free survival; TMA, tissue microarray; ER, estrogen receptor.




Figure S4. Prognostic role of IB-determined ER β status for OS. OS, overall survival; IB, immunoblot; ER, estrogen receptor.




Figure S5. Prognostic role of PCR-determined ER β status for OS. OS, overall survival; PCR, polymerase chain reaction; ER, estrogen receptor.




Figure S6. Funnel plots for assessing publication bias for DFS. Only studies assessing ER β status using IHC were included. DFS, disease-free survival; IHC, immunohistochemistry.




Figure S7. Funnel plots for assessing publication bias for OS. Only studies assessing ER β status using IHC were included. OS, overall survival; IHC, immunohistochemistry.

Supplementary Table S1: Sensitivity analysis of survival in patients with different ERb(Total/ERb1/ERb2) status (IHC).

Endpoints	Pan-ERb				ERb-1			ERb-2							
	Number of studies	Random effect		Study heterogeneity		Number of studies	Random effect		Number of studies	Random effect		Study heterogeneity			
		HR(95%CI)		I ²	p		HR(95%CI)			I ²	p	HR(95%CI)		I ²	p
DFS															
Median follow-up >60 months		N/A			4	0.49(0.30,0.82)		72%	0.010	4	0.63(0.46,0.86)		0%	0.79	
Sample size ≥200		N/A			4	0.72(0.48,1.07)		61%	0.050		N/A				
OS															
Median follow-up >60 months	3	0.60(0.45,0.80)		0%	0.71	4	0.38(0.25,0.58)		0%	1.000	5	0.46(0.32,0.65)		0%	0.92
Sample size ≥200		N/A			3	0.76(0.16,3.47)		93%	<0.001		N/A				

NA, not available.

Supplementary Table S2: Origination and classification of HRs for DFS and OS.

References	Year	Data for DFS	Data for OS
Vinayagam et al.	2007	i,ii	i ,i*,ii
Honma et al.	2008	i ,i*,ii	i ,i*,ii
Novelli et al.	2008	i ,i*	
Gruvberger-Saal et al.	2007	i*,ii	i*
Mann et al.	2001		i
Mahle et al.	2009		i*,ii
Hopp et al.	2004	i,ii	i*,ii
Borgquist et al.	2008	i ,i*	
Palmieri et al.	2004	i,ii	i,ii
Shaaban et al.	2008	ii	i*,ii
Nakopoulou et al.	2004	i*,ii	i*,ii
Myers et al.	2004	i*	
Sugiura et al.	2007	i*,ii	i*,ii
Omoto et al.	2002	i*	
Omoto et al.	2001	i*	
Yan et al.	2011		i*
Zhang et al.	2014	i*	
O'Neill et al.	2004	i*	
Guo et al.	2014	i*,ii	
Chantzi et al.	2013	i,ii	
Qui et al.	2009	i*	i*
Markey et al.	2009	i*	i*,ii
Kim et al.	2012	i*,ii	
Wen et al.	2002	ii	ii
Wimberly et al.	2014	i*,ii	

i Original data derived from univariable analysis ;

i* Extracted data from survival curves as univariable analysis;

ii Original data derived from multivariable analysis ;